Disclosed are uses at least one alpha-1,4/1,6-glycoside hydrolase (GLCH) as a feed additive for a ruminant wherein said hydrolase: (a) has at least 20% activity at pH less than or equal to 3 in the presence of pepsin as compared to activity of the hydrolase at pH 6 in the presence of pepsin, (b) said hydrolase is active in at least two of three digestive chambers of a ruminant comprising a rumen, an abomasum and a small intestine and (c) the hydrolase works with pancreatic amylase to increase glucose yield.

Disclosed are uses at least one alpha-1,4/1,6-glycoside hydrolase (GLCH) as a feed additive for a ruminant wherein said hydrolase: (a) has at least 20% activity at pH less than or equal to 3 in the presence of pepsin as compared to activity of the hydrolase at pH 6 in the presence of pepsin, (b) said hydrolase is active in at least two of three digestive chambers of a ruminant comprising a rumen, an abomasum and a small intestine and (c) the hydrolase works with pancreatic amylase to increase glucose yield.

The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.

The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.

The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.

Disclosed are cationic lipids which are compounds of Formula I. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

##STR00001##

Disclosed are cationic lipids which are compounds of Formula I. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

##STR00001##

A solution for topical application to the skin for therapeutic and regenerative applications comprises about 0.05% by weight of annexin-1, about 0.76% by weight of galectin-1, about 0.23% by weight of protein S-100, about 0.003% by weight of timp-1, about 0.01% by weight of timp-2, about 0.01% by weight of ECM1, about 0.2% by weight of adiponectin, about 0.002% by weight of nephroblastoma overexpressed protein, about 0.0003% by weight of prostacyclin synthase, about 0.001% by weight of C-X-X motif chemokine, about 2% by weight of heparan sulphate, and about 0.01% by weight of apolipoprotein D.

A solution for topical application to the skin for therapeutic and regenerative applications comprises about 0.05% by weight of annexin-1, about 0.76% by weight of galectin-1, about 0.23% by weight of protein S-100, about 0.003% by weight of timp-1, about 0.01% by weight of timp-2, about 0.01% by weight of ECM1, about 0.2% by weight of adiponectin, about 0.002% by weight of nephroblastoma overexpressed protein, about 0.0003% by weight of prostacyclin synthase, about 0.001% by weight of C-X-X motif chemokine, about 2% by weight of heparan sulphate, and about 0.01% by weight of apolipoprotein D.

Sucrose isomerase is used as a nutritional supplement, or can be mixed in with a powderous food/beverage formulation. When an animal, including a human, consumes sucrose, the sucrose isomerase will act on the sucrose present in the food, and will convert the sucrose to other sugars. This results in lowering of the glycemic index of the food without changing the formulation of the food.